{"id":371181,"date":"2026-08-10T04:57:12","date_gmt":"2026-08-10T04:57:12","guid":{"rendered":"https:\/\/www.europesays.com\/africa\/371181\/"},"modified":"2026-08-10T04:57:12","modified_gmt":"2026-08-10T04:57:12","slug":"pfizer-explores-localisation-supply-chain-and-healthcare-partnerships-across-middle-east-africa","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/africa\/371181\/","title":{"rendered":"Pfizer explores localisation, supply-chain and healthcare partnerships across Middle East, Africa"},"content":{"rendered":"


\n
\n \"Rodrigo <\/p>\n

Rodrigo Puga, Regional President – Middle East, Russia and Africa (MERA), Pfizer<\/p>\n

Photo courtesy: Pfizer<\/p>\n


\n
\n In an interview with Zawya Projects, Rodrigo Puga, Regional President for Middle East, Russia and Africa (MERA) at Pfizer Rodrigo Puga, Regional President for Middle East, Russia and Africa (MERA) at Pfizer, outlines the pharma giant’s regional priorities\u2014from AI-driven R&D and supply chain resilience to strategic localisation and public-private partnerships \n <\/p>\n


\n Eman Hamed
\n
\n ,\u00a0
\n ZAWYA Projects \n <\/p>\n

US-based global pharmaceutical and biotechnology giant Pfizer is exploring manufacturing, technology transfer, research and capability-building partnerships across the Middle East and Africa as governments seek greater drug security and access to innovative therapies, according the company\u2019s Regional President for Middle East, Russia and Africa (MERA).<\/p>\n

Disclaimer: This article is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy.\u00a0Read our full disclaimer policy here<\/a>.<\/p>\n

\u00a9 ZAWYA 2026<\/p>\n","protected":false},"excerpt":{"rendered":" Rodrigo Puga, Regional President – Middle East, Russia and Africa (MERA), Pfizer Photo courtesy: Pfizer…\n","protected":false},"author":2,"featured_media":371182,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[5],"tags":[63,7796,15673,1424,12627,177472,40320,1073],"class_list":["post-371181","post","type-post","status-publish","format-standard","has-post-thumbnail","category-africa","tag-africa","tag-healthcare","tag-industrial","tag-investment","tag-manufacturing","tag-mena-countries","tag-pharmaceutical","tag-technology"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@africa\/117069443781773299","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/africa\/wp-json\/wp\/v2\/posts\/371181","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/africa\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/africa\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/africa\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/africa\/wp-json\/wp\/v2\/comments?post=371181"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/africa\/wp-json\/wp\/v2\/posts\/371181\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/africa\/wp-json\/wp\/v2\/media\/371182"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/africa\/wp-json\/wp\/v2\/media?parent=371181"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/africa\/wp-json\/wp\/v2\/categories?post=371181"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/africa\/wp-json\/wp\/v2\/tags?post=371181"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}